SINO BIOPHARMACEUTICALSINO BIOPHARMACEUTICALSINO BIOPHARMACEUTICAL

SINO BIOPHARMACEUTICAL

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪67.36 B‬HKD
‪2.58 B‬HKD
‪28.95 B‬HKD
‪9.64 B‬
Beta (1Y)
1.28
Employees (FY)
‪25.81 K‬
Change (1Y)
−466 −1.77%
Revenue / Employee (1Y)
‪143.63 K‬HKD
Net income / Employee (1Y)
‪10.37 K‬HKD

About SINO BIOPHARMACEUTICAL


CEO
S Y Tse
Headquarters
Hong Kong
Founded
2000
FIGI
BBG000C6XDL4
Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Investment, Modernised Chinese Medicines and Chemical Medicines; and Others. The Investment segment offers long-term investments. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long-term investments. The Other segment includes a research and development sector, which provides services to third parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse Cheung Ling Cheng and on February 2, 2000, and is headquartered in Hong Kong.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 1177 is 3.60 HKD — it has increased by 1.98% in the past 24 hours. Watch SINO BIOPHARMACEUTICAL stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange SINO BIOPHARMACEUTICAL stocks are traded under the ticker 1177.
1177 stock has risen by 2.27% compared to the previous week, the month change is a −2.17% fall, over the last year SINO BIOPHARMACEUTICAL has showed a 16.50% increase.
We've gathered analysts' opinions on SINO BIOPHARMACEUTICAL future price: according to them, 1177 price has a max estimate of 7.01 HKD and a min estimate of 2.96 HKD. Watch 1177 chart and read a more detailed SINO BIOPHARMACEUTICAL stock forecast: see what analysts think of SINO BIOPHARMACEUTICAL and suggest that you do with its stocks.
1177 reached its all-time high on Jul 22, 2020 with the price of 11.24 HKD, and its all-time low was 0.07 HKD and was reached on Jan 14, 2004. View more price dynamics on 1177 chart.
See other stocks reaching their highest and lowest prices.
1177 stock is 3.12% volatile and has beta coefficient of 1.28. Track SINO BIOPHARMACEUTICAL stock price on the chart and check out the list of the most volatile stocks — is SINO BIOPHARMACEUTICAL there?
Today SINO BIOPHARMACEUTICAL has the market capitalization of ‪64.73 B‬, it has decreased by −0.57% over the last week.
Yes, you can track SINO BIOPHARMACEUTICAL financials in yearly and quarterly reports right on TradingView.
SINO BIOPHARMACEUTICAL is going to release the next earnings report on Mar 28, 2025. Keep track of upcoming events with our Earnings Calendar.
1177 earnings for the last half-year are 0.08 HKD per share, whereas the estimation was 0.08 HKD, resulting in a 9.43% surprise. The estimated earnings for the next half-year are 0.08 HKD per share. See more details about SINO BIOPHARMACEUTICAL earnings.
SINO BIOPHARMACEUTICAL revenue for the last half-year amounts to ‪17.06 B‬ HKD, despite the estimated figure of ‪16.28 B‬ HKD. In the next half-year revenue is expected to reach ‪16.72 B‬ HKD.
1177 net income for the last half-year is ‪1.56 B‬ HKD, while the previous report showed ‪1.16 B‬ HKD of net income which accounts for 34.87% change. Track more SINO BIOPHARMACEUTICAL financial stats to get the full picture.
SINO BIOPHARMACEUTICAL dividend yield was 1.44% in 2023, and payout ratio reached 35.95%. The year before the numbers were 2.63% and 75.57% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 2, 2024, the company has ‪25.81 K‬ employees. See our rating of the largest employees — is SINO BIOPHARMACEUTICAL on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SINO BIOPHARMACEUTICAL EBITDA is ‪7.61 B‬ HKD, and current EBITDA margin is 25.87%. See more stats in SINO BIOPHARMACEUTICAL financial statements.
Like other stocks, 1177 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SINO BIOPHARMACEUTICAL stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SINO BIOPHARMACEUTICAL technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SINO BIOPHARMACEUTICAL stock shows the neutral signal. See more of SINO BIOPHARMACEUTICAL technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.